<DOC>
	<DOCNO>NCT02123316</DOCNO>
	<brief_summary>To evaluate efficacy extract Dermatophagoides pteronyssinus versus placebo treatment local allergic rhinitis . The primary efficacy endpoint reduction symptom score medication use active group compare placebo . The influence treatment `` vitro '' `` vivo '' objective parameter also assess .</brief_summary>
	<brief_title>Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus Local Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Prior study specific examination patient give his/her write informed consent . Local allergic rhinitis induce Dermatophagoides pteronyssinus ( DP ) . Age : 1855 . Negative skin pricktest DP Positive nasal allergen provocation test DP ( NAPTDP ) and/or nasal specific IgE ( sIgE ) DP &gt; 0.35 kU/L If applicable negative urine pregnancy test willingness use effective form contraception duration involvement study . Severe immunopathological immunodeficiency diseases . Treatment betablockers , even administer topically Severe psychological disorder Severe Atopic Dermatitis FEV1 &lt; 70 % predicted appropriate pharmacological treatment History hypersensitivity intolerance excipients / trial medication medication use protocol Inability adequately perform diagnostic test treatment Awareness inhale allergen ( perennial seasonal ) clinically relevant subject may interfere response evaluation Treatment immunotherapy 5 year prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>local allergic rhinitis</keyword>
	<keyword>subcutaneous immunotherapy</keyword>
	<keyword>house dust mite allergy</keyword>
	<keyword>Dermatophagoides pteronyssinus allergy</keyword>
</DOC>